Search

everythinglearnresearchcommunity

for

Search:↓

Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

Microneedle pens for hair loss are harder to find on Amazon due to FDA regulations on needle length. Users suggest buying from AliExpress or Temu instead.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

A user questions the authenticity of a cheap minoxidil product due to packaging errors and unusual smell, considering returning it. They also reference an FDA report for further information.

Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. There is skepticism about claims of a breakthrough, despite FDA approval for human trials.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

The conversation is about starting microneedling for hair growth, with questions on needle sizes, session frequency, and reliable purchasing options. The user seeks clarity on FDA regulations and prefers to avoid certain online retailers.

The conversation is about the effectiveness and safety of a hair loss treatment called Pyri, with users discussing its availability and comparing it to other treatments like RU58841, fluridil, and alfatradiol. Some users are waiting for FDA approval before using Pyri, while others share their positive experiences with RU58841 and suggest additional treatments with minimal side effects.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Eucapil's effectiveness is questioned due to unconvincing clinical trial and lack of FDA approval.

HairClone received grant money to start work after crowdfunding failed. They aim to offer treatments in early 2021, pending UK FDA licensing.

The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

The conversation discusses the effectiveness of Exosomes as a hair loss treatment. A user recalls a doctor on Youtube showcasing successful results from using Exosomes.

The conversation discusses hair regrowth using dissolvable microneedles loaded with rapamycin and epigallocatechin gallate nanoparticles. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Hair loss discussion focused on exosomes as a potential treatment. Users shared experiences and asked if anyone tried or was offered this method.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

Follica's preferred microneedling protocol for hair growth, which includes needle depth, frequency and movement parameters as well as the use of topical treatments such as minoxidil and finasteride.

Oral minoxidil dosing should be based on body weight to minimize side effects, with higher doses increasing risks like pericardial effusion. Combining oral minoxidil with topical treatments and finasteride can improve hair growth, but regular heart health monitoring is essential.

Low-dose dutasteride (0.1 mg) is effective for hair growth, potentially more so than finasteride, with fewer side effects. East Asians may respond well to these treatments due to hair characteristics.

A new plant-based serum is claimed to regrow hair in weeks, but users are skeptical about its effectiveness and the reliability of the study. Ingredients like Centella Asiatica and IGF-1 are mentioned, but many doubt the serum's superiority over existing treatments like Minoxidil and finasteride.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

Some users report encouraging results with laser caps for hair loss, while others see no improvement. Treatments mentioned include low-level laser therapy, Minoxidil, and finasteride.

A humorous take on hair loss treatments, mentioning the use of minoxidil, finasteride, dutasteride, and unconventional methods. The conversation includes satire about extreme and fictional hair growth rituals.

The user experienced a receding hairline and tried minoxidil, which may have slowed the process but caused puffy eyes. They are hesitant to use finasteride and suspect oily dandruff might be an aggravator.

The method combines finasteride, minoxidil, intense leg exercises, and cold exposure to treat androgenetic alopecia. It aims to boost metabolism and reduce androgenic effects, enhancing hair growth.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.